Robin Knifsend

Robin has served as Synthekine’s Senior Vice President of Finance and Operations since April 2021. She has more than 25 years of industry experience spanning equity financings, research and development collaborations, acquisitions and commercial product launches. Prior to joining Synthekine, Robin was senior vice president of finance and principal accounting officer at CytomX Therapeutics and responsible for finance, tax and planning. Previously, she had several roles of increasing responsibility at Actelion Pharmaceuticals US where she oversaw the finance and corporate services functions, helped launch three pharmaceutical products and led the finance integration into Janssen Pharmaceuticals as a result of the acquisition by Johnson & Johnson. She has also held financial leadership roles at life science and high technology companies including Maxygen, Inc., Chiron Corporation, SNOWBALL.com and Vividence Corporation. She began her career in public accounting at Arthur Andersen in the advisory and tax practice. Robin holds a bachelor of science degree in agricultural and managerial economics from the University of California, Davis, and is a certified public accountant in the state of California.